NN 7129
/ Novo Nordisk
- LARVOL DELTA
Home
Next
Prev
1 to 8
Of
8
Go to page
1
October 27, 2011
Interim financial report for the period 1 January 2011 to 30 September 2011
(Novo Nordisk)
- Longer-acting recombinant factor VIIa derivative, NN-7128/NN-7129, discontinued following further analysis of the P2 results for the longer-acting recombinant factor VIIa derivative, N7-GP; Novo Nordisk has decided to discontinue development of this compound for prophylactic treatment in hemophilia pts with inhibitors
Product discontinuation • Hemophilia
May 04, 2020
"discounts https://t.co/ES0yNVN7gP"
(@dramypark)
February 25, 2020
"The @US_FDA has issued a warning to @jimmyjohns: https://t.co/qLvWxN7SGP"
(@jasonfechner)
January 07, 2020
"Australian bushfire smoke drifts to South America - WMO https://t.co/n7gpMCZfFA"
(@Reuters)
August 01, 2019
"#HCPs: #CDC expert outlines how you can stop surge of congenital #syphilis in THIS @Medscape video -->https://t.co/VRWkn7IGpV"
(@CDCSTD)
Video
June 05, 2019
"#HCPs: #CDC expert outlines how you can stop surge of congenital #syphilis in THIS @Medscape video -->https://t.co/VRWkn7IGpV."
(@CDCSTD)
Video
June 02, 2019
"#HCPs: #CDC expert outlines how you can stop surge of congenital #syphilis in THIS @Medscape video -->https://t.co/VRWkn7IGpV."
(@CDCSTD)
Video
January 29, 2019
"@Medscape NEW Video: #CDC expert on how healthcare providers can stop surge of congenital #syphilis -->https://t.co/VRWkn7IGpV"
(@CDCSTD)
Video
1 to 8
Of
8
Go to page
1